Anti-Influenza Drug Discovery: Are We Ready for the Next Pandemic?

Advances in Carbohydrate Chemistry and Biochemistry

Volumn 61, Issue , 2007, Pages 293-352

  Islam, Tasneem ^a   von Itzstein, Mark ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; SIALIDASE; ZANAMIVIR;

BINDING SITE; CATALYSIS; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PANDEMIC; PREVENTION AND CONTROL; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; CATALYSIS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; INFLUENZA, HUMAN; NEURAMINIDASE; ORTHOMYXOVIRIDAE;

EID: 34948898078     PISSN: 00652318     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2318(07)61006-3     Document Type: Review

References (151)

1. Potter C.W. A history of influenza. J. Appl. Microbiol. 91 (2001) 572-579
2. Crosby A.W. America's Forgotten Pandemic (1989), Cambridge University Press, Cambridge
3. Douglas R.G.J. Drug therapy, prophylaxis and treament of influenza. N. Engl. J. Med. 322 (1990) 443-450
4. Wintermeyer S.M., and Nahata M.C. Rimantidine: A clinical perspective. Ann. Pharmacother. 29 (1995) 299-310
5. Pinto L.H., Holsinger L.J., and Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell 69 (1992) 517-528
6. Hay A.J. The action of adamantanamines against influenza A viruses: Inhibition of the M2 ion channel protein. Semin. Virol. 3 (1992) 21-30
7. Hay A.J., Thompson C.A., Geraghty A., Hayhurst S., Grambas S., and Bennett M.S. In: Hannoun C. (Ed). Options for the Control of Influenza Virus Vol. II (1993), Excerpta Medica, Amsterdam 281-288
8. McKimm-Breschkin J.L. Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opin. Pharmacother. 3 (2002) 103-112
9. Gubareva L.V., Kaiser L., and Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 355 (2000) 827-835
10. Zhang J., and Xu W. Recent advances in anti-influenza agents with neuraminidase as target. Mini Rev. Med. Chem. 6 (2006) 429-448
11. Webster R.G., Schafer J.R., Suss J., Bean W.J., and Kawaoko Y. In: Hannoun (Ed). Options for the control of influenza virus II (1993), Excerpta Medica, Amsterdam 177-185
12. Wagner R., Matrosovich M., and Klenk H.-D. Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12 (2002) 159-166
13. Oxford J.S. Influenza A pandemics of the 20th century with special reference to 1918: Virology, pathology and epidemiology. Rev. Med. Virol. 10 (2000) 119-133
14. Herrler G., Hausmann J., and Klenk H.-D. In: Rosenberg A. (Ed). Biology of the Sialic Acids (1995), Plenum Press, New York 315-336
15. Wiley D.C., and Skehel J.J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56 (1987) 365-394
16. Couceiro J.N., Paulson J.C., and Baum L.G. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29 (1993) 155-165
17. Suzuki Y., Ito T., Suzuki T., Holland Jr. R.E., Chambers T.M., Kiso M., Ishida H., and Kawaoka Y. Sialic acid species as a determinant of the host range of influenza A viruses. J. Virol. 74 (2000) 11825-11831
18. Skehel J.J., and Wiley D.C. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 69 (2000) 531-569
19. Matrosovich M., and Klenk H.-D. Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding. Rev. Med. Virol. 13 (2003) 85-97
20. Borrego-Diaz E., Peeples M.E., Markosyan R.M., Melikyan G.B., and Cohen F.S. Completion of trimeric hairpin formation of influenza virus hemagglutinin promotes fusion pore opening and enlargement. Virology 316 (2003) 234-244
21. Sauter N.K., Bednarski M.D., Wurzburg B.A., Hanson J.E., Whitesides G.M., Skehel J.J., and Wiley D.C. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: A 500-MHz proton nuclear magnetic resonance study. Biochemistry 28 (1989) 8388-8396
22. Bullough P.A., Hughson F.M., Treharne A.C., Ruigrok R.W., Skehel J.J., and Wiley D.C. Crystals of a fragment of influenza haemagglutinin in the low pH induced conformation. J. Mol. Biol. 236 (1994) 1262-1265
23. Colman P.M., and Ward C.W. Structure and diversity of influenza virus neuraminidase. Curr. Top. Microbiol. Immunol. 114 (1985) 177-255
24. Varghese J.N., Laver W.G., and Colman P.M. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303 (1983) 35-40
25. Colman P.M., Varghese J.N., and Laver W.G. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303 (1983) 41-44
26. Air G.M., and Laver W.G. The neuraminidase of influenza virus. Proteins 6 (1989) 341-356
27. Colman P.M. Influenza virus neuraminidase: Structure, antibodies, and inhibitors. Protein Sci. 3 (1994) 1687-1696
28. Gottschalk A. The structure of the prosthetic group of bovine submaxillary gland mucoprotein. Biochim. Biophys. Acta 24 (1957) 649-650
29. Gottschalk A. Neuraminidase: its substrate and mode of action. Adv. Enzymol. Relat. Subj. Biochem. 20 (1958) 135-146
30. Palese P., Tobita K., Ueda M., and Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61 (1974) 397-410
31. Palese P., and Compans R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of action. J. Gen. Virol. 33 (1976) 159-163
32. Corfield A.P., and Schauer R. In: Schauer R. (Ed). Sialic Acids-Chemistry, Metabolism and Function (1982), Springer-Verlag, Wien 195-261
33. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 353 (2005) 1363-1373
34. Watson J.N., Newstead S., Narine A.A., Taylor G., and Bennet A.J. Two nucleophilic mutants of the Micromonospora viridifaciens sialidase operate with retention of configuration by two different mechanisms. Chembiochem 6 (2005) 1999-2004
35. Watson J.N., Newstead S., Dookhun V., Taylor G., and Bennet A.J. Contribution of the active site aspartic acid to catalysis in the bacterial neuraminidase from Micromonospora viridifaciens. FEBS Lett. 577 (2004) 265-269
36. Watson J.N., Dookhun V., Borgford T.J., and Bennet A.J. Mutagenesis of the conserved active-site tyrosine changes a retaining sialidase into an inverting sialidase. Biochemistry 42 (2003) 12682-12690
37. Miller C.A., Wang P., and Flashner M. Mechanism of Arthrobacter sialophilus neuraminidase: The binding of substrates and transition-state analogs. Biochem. Biophys. Res. Commun. 83 (1978) 1479-1487
38. Varghese J.N., McKimm-Breschkin J.L., Caldwell J.B., Kortt A.A., and Colman P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14 (1992) 327-332
39. Burmeister W.P., Henrissat B., Bosso C., Cusack S., and Ruigrok R.W. Influenza B virus neuraminidase can synthesize its own inhibitor. Structure 1 (1993) 19-26
40. Chong A.K., Pegg M.S., Taylor N.R., and von Itzstein M. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur. J. Biochem. 207 (1992) 335-343
41. Taylor N.R., and von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 37 (1994) 616-624
42. Rye C.S., and Withers S.G. Glycosidase mechanisms. Curr. Opin. Chem. Biol. 4 (2000) 573-580
43. Ly H.D., and Withers S.G. Mutagenesis of glycosidases. Annu. Rev. Biochem. 68 (1999) 487-522
44. Zechel D.L., and Withers S.G. Dissection of nucleophilic and acid-base catalysis in glycosidases. Curr. Opin. Chem. Biol. 5 (2001) 643-649
45. Varghese J.N., and Colman P.M. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution. J. Mol. Biol. 221 (1991) 473-486
46. Baker A.T., Varghese J.N., Laver W.G., Air G.M., and Colman P.M. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 2 (1987) 111-117
47. Bossart-Whitaker P., Carson M., Babu Y.S., Smith C.D., Laver W.G., and Air G.M. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J. Mol. Biol. 232 (1993) 1069-1083
48. Burmeister W.P., Ruigrok R.W., and Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 11 (1992) 49-56
49. Stoll V., Stewart K.D., Maring C.J., Muchmore S., Giranda V., Gu Y.G., Wang G., Chen Y., Sun M., Zhao C., Kennedy A.L., Madigan D.L., Xu Y., Saldivar A., Kati W., Laver G., Sowin T., Sham H.L., Greer J., and Kempf D. Influenza neuraminidase inhibitors: Structure-based design of a novel inhibitor series. Biochemistry 42 (2003) 718-727
50. Bamford M.J. Neuraminidase inhibitors as potential anti-influenza drugs. J. Enzyme Inhib. 10 (1995) 1-16
51. Haskell T.H., Peterson F.E., Watson D., Plessas N.R., and Culbertson T. Neuraminidase inhibition and viral chemotherapy. J. Med. Chem. 13 (1970) 697-704
52. Edmond J.D., Johnston R.G., Kidd D., Rylance H.J., and Sommerville R.G. The inhibition of neuraminidase and antiviral action. Br. J. Pharmacol. Chemother. 27 (1966) 415-426
53. Suzuki Y., Sato K., Kiso M., and Hasegawa A. New ganglioside analogs that inhibit influenza virus sialidase. Glycoconj. J. 7 (1990) 349-354
54. Hagiwara T., Kijima-Suda I., Ido T., Ohrui H., and Tomita K. Inhibition of bacterial and viral sialidases by 3-fluoro-N-acetylneuraminic acid. Carbohydr. Res. 263 (1994) 167-172
55. White C.L., Janakiraman M.N., Laver W.G., Philippon C., Vasella A., Air G.M., and Luo M. A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies. J. Mol. Biol. 245 (1995) 623-634
56. Meindl P., and Tuppy H. 2-Deoxy-2,3-dehydrosialic acids. II. Competitive inhibition of Vibrio cholerae neuraminidase by 2-deoxy-2,3-dehydro-N-acylneuraminic acids. Hoppe Seylers Z Physiol. Chem. 350 (1969) 1088-1092
57. Holzer C.T., von Itzstein M., Jin B., Pegg M.S., Stewart W.P., and Wu W.Y. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. Glycoconj. J. 10 (1993) 40-44
58. Meindl P., Bodo G., Palese P., Schulman J., and Tuppy H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 58 (1974) 457-463
59. Nohle U., Beau J.M., and Schauer R. Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycoloylneuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat. Eur. J. Biochem. 126 (1982) 543-548
60. Palese P., Schulman J.L., Bodo G., and Meindl P. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 59 (1974) 490-498
61. Palese P., and Schulman J.L. Inhibitors of viral neuraminidase as potential antiviral drugs. Chemoprophylaxis Virus Infect. Respir. Tract, 1 (1977) 189-205
62. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., and Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993) 418-423
63. Goodford P.J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28 (1985) 849-857
64. von Itzstein M., Dyason J.C., Oliver S.W., White H.F., Wu W.Y., Kok G.B., and Pegg M.S. A study of the active site of influenza virus sialidase: An approach to the rational design of novel anti-influenza drugs. J. Med. Chem. 39 (1996) 388-391
65. L.M. von Itzstein, W.Y. Wu, V. Phan Tho, B. Danylec, and B. Jin, Preparation of Derivatives and Analogs of 2-Deoxy-2,3-Didehydro-N-Acetylneuraminic Acid as Antiviral Agents, Biota Scientific Management Pty. Ltd., Australia, 1991, WO 9116320.
66. von Itzstein M., Wu W.Y., and Jin B. The synthesis of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid: A potent influenza virus sialidase inhibitor. Carbohydr. Res. 259 (1994) 301-305
67. von Itzstein M., Jin B., Wu W.Y., and Chandler M. A convenient method for the introduction of nitrogen and sulfur at C-4 on a sialic acid analog. Carbohydr. Res. 244 (1993) 181-185
68. Chandler M., Bamford M.J., Conroy R., Lamont B., Patel B., Patel V.K., Steeples I.P., Storer R., Weir N.G., Wright M., and Williamson C. Synthesis of the potent influenza neuraminidase inhibitor 4-guanidino Neu5Ac2en. X-ray molecular structure of 5-acetamido-4-amino-2,6-anhydro-3,4,5-trideoxy-d-erythro-l-gluco-nonioni c acid. J. Chem. Soc. Perkin Trans. 1 (1995) 1173-1180
69. Woods J.M., Bethell R.C., Coates J.A., Healy N., Hiscox S.A., Pearson B.A., Ryan D.M., Ticehurst J., Tilling J., Walcott S.M., et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob. Agents Chemother. 37 (1993) 1473-1479
70. Wallace A.C., Laskowski R.A., and Thornton J.M. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8 (1995) 127-134
71. Sidwell R.W., and Smee D.F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral. Res. 48 (2000) 1-16
72. Flashner M., Kessler J., and Tanenbaum S.W. The interaction of substrate-related ketals with bacterial and viral neuraminidases. Arch. Biochem. Biophys. 221 (1983) 188-196
73. Driguez P.-A., Barrere B., Quash G., and Doutheau A. Synthesis of transition-state analogues as potential inhibitors of sialidase from influenza virus. Carbohydr. Res. 262 (1994) 297-310
74. Ikeda K., Sano K., Ito M., Saito M., Hidari K., Suzuki T., Suzuki Y., and Tanaka K. Synthesis of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid analogues modified at the C-4 and C-9 positions and their behaviour towards sialidase from influenza virus and pig liver membrane. Carbohydr. Res. 330 (2001) 31-41
75. Ikeda K., Kimura F., Sano K., Suzuki Y., and Achiwa K. Chemoenzymatic synthesis of an N-acetylneuraminic acid analogue having a carbamoylmethyl group at C-4 as an inhibitor of sialidase from influenza virus. Carbohydr. Res. 312 (1998) 183-189
76. Li J., Zheng M., Tang W., He P.L., Zhu W., Li T., Zuo J.P., Liu H., and Jiang H. Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities. Bioorg. Med. Chem. Lett. 16 (2006) 5009-5013
77. Wilson J.C., Thomson R.J., Dyason J.C., Florio P., Quelch K.J., Abo S., and von Itzstein M. The design, synthesis and biological evaluation of neuraminic acid-based probes of Vibrio cholerae sialidase. Tetrahedron Asymmetry 11 (2000) 53-73
78. Starkey I.D., Mahmoudian M., Noble D., Smith P.W., Cherry P., Howes P.D., and Sollis S.L. Synthesis and influenza virus sialidase inhibitory activity of the 5-desacetamido analog of 2,3-didehydro-2,4-dideoxy-4-guanidinyl-N-acetylneuraminic acid (GG167). Tetrahedron Lett. 36 (1995) 299-302
79. Schreiner E., Zbiral E., Kleineidam R.G., and Schauer R. 2,3-Didehydro-2-deoxysialic acids structurally varied at C-5 and their behaviour towards the sialidase from Vibrio cholerae. Carbohydr. Res. 216 (1991) 61-66
80. Smith P.W., Starkey I.D., Howes P.D., Sollis S.L., Keeling S.P., Cherry P.C., von Itzstein M., Wu W.Y., and Jin B. Synthesis and influenza virus sialidase inhibitory activity of analogs of 4-guanidino-Neu5Ac2en (GG167) with modified 5-substituents. Eur. J. Med. Chem. 31 (1996) 143-150
81. Honda T., Masuda T., Yoshida S., Arai M., Kobayashi Y., and Yamashita M. Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives. Bioorg. Med. Chem. Lett. 12 (2002) 1921-1924
82. Honda T., Masuda T., Yoshida S., Arai M., Kaneko S., and Yamashita M. Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir. Bioorg. Med. Chem. Lett. 12 (2002) 1925-1928
83. Andrews D.M., Cherry P.C., Humber D.C., Jones P.S., Keeling S.P., Martin P.F., Shaw C.D., and Swanson S. Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain. Eur. J. Med. Chem. 34 (1999) 563-574
84. McKimm-Breschkin J.L., Colman P.M., Jin B., Krippner G.Y., McDonald M., Reece P.A., Tucker S.P., Waddington L., Watson K.G., and Wu W.Y. Tethered neuraminidase inhibitors that bind an influenza virus: A first step towards a diagnostic method for influenza. Angew. Chem. Int. Ed. Engl. 42 (2003) 3118-3121
85. Honda T., Yoshida S., Arai M., Masuda T., and Yamashita M. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Bioorg. Med. Chem. Lett. 12 (2002) 1929-1932
86. Masuda T., Yoshida S., Arai M., Kaneko S., Yamashita M., and Honda T. Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives. Chem. Pharm. Bull. (Tokyo) 51 (2003) 1386-1398
87. Watson K.G., Cameron R., Fenton R.J., Gower D., Hamilton S., Jin B., Krippner G.Y., Luttick A., McConnell D., MacDonald S.J., Mason A.M., Nguyen V., Tucker S.P., and Wu W.Y. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase. Bioorg. Med. Chem. Lett. 14 (2004) 1589-1592
88. Macdonald S.J., Cameron R., Demaine D.A., Fenton R.J., Foster G., Gower D., Hamblin J.N., Hamilton S., Hart G.J., Hill A.P., Inglis G.G., Jin B., Jones H.T., McConnell D.B., McKimm-Breschkin J., Mills G., Nguyen V., Owens I.J., Parry N., Shanahan S.E., Smith D., Watson K.G., Wu W.Y., and Tucker S.P. Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem. 48 (2005) 2964-2971
89. Macdonald S.J., Watson K.G., Cameron R., Chalmers D.K., Demaine D.A., Fenton R.J., Gower D., Hamblin J.N., Hamilton S., Hart G.J., Inglis G.G., Jin B., Jones H.T., McConnell D.B., Mason A.M., Nguyen V., Owens I.J., Parry N., Reece P.A., Shanahan S.E., Smith D., Wu W.Y., and Tucker S.P. Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen. Antimicrob. Agents Chemother. 48 (2004) 4542-4549
90. Kok G.B., Campbell M., Mackey B., and von Itzstein M. Synthesis and biological evaluation of sulfur isosteres of the potent influenza virus sialidase inhibitors 4-amino-4-deoxy- and 4-deoxy-4-guanidino-Neu5Ac2en. J. Chem. Soc. Perkin Trans. 1 (1996) 2811-2815
91. Smith B.J., Colman P.M., Von Itzstein M., Danylec B., and Varghese J.N. Analysis of inhibitor binding in influenza virus neuraminidase. Protein Sci. 10 (2001) 689-696
92. Murakami M., Ikeda K., and Achiwa K. Chemoenzymatic synthesis of neuraminic acid analogs structurally varied at C-5 and C-9 as potential inhibitors of the sialidase from influenza virus. Carbohydr. Res. 280 (1996) 101-110
93. Lentz M.R., Webster R.G., and Air G.M. Site-directed mutation of the active site of influenza neuraminidase and implications for the catalytic mechanism. Biochemistry 26 (1987) 5351-5358
94. Bamford M.J., Pichel J.C., Husman W., Patel B., Storer R., and Wier N.G. Synthesis of 6-, 7- and 8-carbon sugar analogs of potent anti-influenza 2,3-didehydro-2,3-dideoxy-N-acetylneuraminic acid derivatives. J. Chem. Soc. Perkin Trans. 1 (1995) 1181-1187
95. Sollis S.L., Smith P.W., Howes P.D., Cherry P.C., and Bethell R.C. Novel inhibitors of influenza sialidase related to GG167. Synthesis of 4-amino and guanidino-4H-pyran-2-carboxylic acid-6-propylamides; selective inhibitors of influenza A virus sialidase. Bioorg. Med. Chem. Lett. 6 (1996) 1805-1808
96. Smith P.W., Sollis S.L., Howes P.D., Cherry P.C., Starkey I.D., Cobley K.N., Weston H., Scicinski J., Merritt A., Whittington A., Wyatt P., Taylor N., Green D., Bethell R., Madar S., Fenton R.J., Morley P.J., Pateman T., and Beresford A. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides. J. Med. Chem. 41 (1998) 787-797
97. Wyatt P.G., Coomber B.A., Evans D.N., Jack T.I., Fulton H.E., Wonacott A.J., Colman P., and Varghese J. Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides. Bioorg. Med. Chem. Lett. 11 (2001) 669-673
98. Smith P.W., Sollis S.L., Howes P.D., Cherry P.C., Cobley K.N., Taylor H., Whittington H.R., Bethell R.C., Taylor N., Varghese J.N., Colman P.M., Singh O., Slkarzynski T., Cleasby A., and Wonacott A.J. Novel inhibitors of influenza sialidases related to GG167. Structure-activity, crystallographic and molecular dynamics studies with 4H-pyran-2-carboxylic acid 6-carboxamides. Bioorg. Med. Chem. Lett. 6 (1996) 2931-2936
99. Taylor N.R., Cleasby A., Singh O., Skarzynski T., Wonacott A.J., Smith P.W., Sollis S.L., Howes P.D., Cherry P.C., Bethell R., Colman P., and Varghese J. Dihydropyrancarboxamides related to zanamivir: A new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 41 (1998) 798-807
100. Smith P.W., Robinson J.E., Evans D.N., Sollis S.L., Howes P.D., Trivedi N., and Bethell R.C. Sialidase inhibitors related to zanamivir: Synthesis and biological evaluation of 4H-pyran 6-ether and ketone. Bioorg. Med. Chem. Lett. 9 (1999) 601-604
101. Smith P.W., and Whittington A.R. Novel inhibitors of influenza sialidases related to zanamivir. Heterocyclic replacements of the glycerol sidechain. Bioorg. Med. Chem. Lett. 7 (1997) 2239-2242
102. Mann M.C., Thomson R.J., Dyason J.C., McAtamney S., and von Itzstein M. Modelling, synthesis and biological evaluation of novel glucuronide-based probes of Vibrio cholerae sialidase. Bioorg. Med. Chem. 14 (2006) 1518-1537
103. Mann M.C., Islam T., Dyason J.C., Florio P., Trower C.J., Thomson R.J., and von Itzstein M. Unsaturated N-acetyl-d-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase. Glycoconj. J. 23 (2006) 127-133
104. Mann M.C., Thomson R.J., and von Itzstein M. An efficient approach to N-acetyl-d-glucosaminuronic acid-based sialylmimetics as potential sialidase inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 5555-5558
105. Florio P., Thomson R.J., Alafaci A., Abo S., and von Itzstein M. Synthesis of δ 4-β-d-glucopyranosiduronic acids as mimetics of 2,3-unsaturated sialic acids for sialidase inhibition. Bioorg. Med. Chem. Lett. 9 (1999) 2065-2068
106. P. Florio, R.J. Thomson, B. Smith, P.M. Colman, and M. von Itzstein, unpublished data.
107. Sasaki K., Nishida Y., Kambara M., Uzawa H., Takahashi T., Suzuki T., Suzuki Y., and Kobayashi K. Design of N-acetyl-6-sulfo-beta-d-glucosaminide-based inhibitors of influenza virus sialidase. Bioorg. Med. Chem. 12 (2004) 1367-1375
108. Sasaki K., Nishida Y., Uzawa H., and Kobayashi K. N-Acetyl-6-sulfo-d-glucosamine as a promising mimic of N-acetyl neuraminic acid. Bioorg. Med. Chem. Lett. 13 (2003) 2821-2823
109. Jedrzejas M.J., Singh S., Brouillette W.J., Laver W.G., Air G.M., and Luo M. Structures of aromatic inhibitors of influenza virus neuraminidase. Biochemistry 34 (1995) 3144-3151
110. Singh S., Jedrzejas M.J., Air G.M., Luo M., Laver W.G., and Brouillette W.J. Structure-based inhibitors of influenza virus sialidase: A benzoic acid lead with novel interaction. J. Med. Chem. 38 (1995) 3217-3225
111. Chand P., Babu Y.S., Bantia S., Chu N., Cole L.B., Kotian P.L., Laver W.G., Montgomery J.A., Pathak V.P., Petty S.L., Shrout D.P., Walsh D.A., and Walsh G.M. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. J. Med. Chem. 40 (1997) 4030-4052
112. Sudbeck E.A., Jedrzejas M.J., Singh S., Brouillette W.J., Air G.M., Laver W.G., Babu Y.S., Bantia S., Chand P., Chu N., Montgomery J.A., Walsh D.A., and Luo M. Guanidinobenzoic acid inhibitors of influenza virus neuraminidase. J. Mol. Biol. 267 (1997) 584-594
113. Howes P.D., Cleasby A., Evans D.N., Fielden H., Smith P.W., Sollis S.L., Taylor N., and Wonacott A.J. 4-Acetylamino-3-(imidazol-1-yl)-benzoic acids as novel inhibitors of influenza sialidase. Eur. J. Med. Chem. 34 (1999) 225-234
114. Brouillette W.J., Atigadda V.R., Duarte F., Luo M., Air G.M., Babu Y.S., and Bantia S. Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping. (Erratum to document cited in CA131:266560). Bioorg. Med. Chem. Lett. 9 (1999) 3259
115. Finley J.B., Atigadda V.R., Duarte F., Zhao J.J., Brouillette W.J., Air G.M., and Luo M. Novel aromatic inhibitors of influenza virus neuraminidase make selective interactions with conserved residues and water molecules in the active site. J. Mol. Biol. 293 (1999) 1107-1119
116. Atigadda V.R., Brouillette W.J., Duarte F., Ali S.M., Babu Y.S., Bantia S., Chand P., Chu N., Montgomery J.A., Walsh D.A., Sudbeck E.A., Finley J., Luo M., Air G.M., and Laver G.W. Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent. J. Med. Chem. 42 (1999) 2332-2343
117. Williams M., Bischofberger N., Swaminathan S., and Kim C.U. Synthesis and influenza neuraminidase inhibitory activity of aromatic analogs of sialic acid. Bioorg. Med. Chem. Lett. 5 (1995) 2251-2254
118. Chand P., Kotian P.L., Morris P.E., Bantia S., Walsh D.A., and Babu Y.S. Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase. Bioorg. Med. Chem. 13 (2005) 2665-2678
119. Brouillette W.J., Atigadda V.R., Luo M., Air G.M., Babu Y.S., and Bantia S. Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping. Bioorg. Med. Chem. Lett. 9 (1999) 1901-1906
120. Vorwerk S., and Vasella A. Carbocyclic analogs of N-acetyl-2,3-didehydro-2-deoxy-d-neuraminic acid (Neu5Ac2en, DANA): Synthesis and inhibition of viral and bacterial neuraminidases. Angew. Chem. Int. Ed. 37 (1998) 1732-1734
121. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y., Laver W.G., and Stevens R.C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119 (1997) 681-690
122. Kim C.U., Lew W., Williams M.A., Wu H., Zhang L., Chen X., Escarpe P.A., Mendel D.B., Laver W.G., and Stevens R.C. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J. Med. Chem. 41 (1998) 2451-2460
123. Lew W., Williams M.A., Mendel D.B., Escarpe P.A., and Kim C.U. C3-Thia and C3-carba isosteres of a carbocyclic influenza neuraminidase inhibitor, (3R,4R,5R)-4-acetamido-5-amino-3-propoxy-1-cyclohexene-1-carboxylic acid. Bioorg. Med. Chem. Lett. 7 (1997) 1843-1846
124. Lew W., Chen X., and Kim C.U. Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 7 (2000) 663-672
125. Kerrigan S.A., Smith P.W., and Stoodley R.J. Synthesis of (4R*,5R*)-4-acetylamino-5-diethylcarbamoylcyclohex-1-ene-1-c arboxylic acid and (3R*,4R*)-4-acetylamino-3-diethylcarbamoylcyclohex-1-ene-1-c arboxylic acid: New inhibitors of influenza virus sialidases. Tetrahedron Lett. 42 (2001) 4709-4712
126. Williams M.A., Lew W., Mendel D.B., Tai C.Y., Escarpe P.A., Laver W.G., Stevens R.C., and Kim C.U. Structure-activity relationships of carbocyclic influenza neuraminidase inhibitors. Bioorg. Med. Chem. Lett. 7 (1997) 1837-1842
127. Li W., Escarpe P.A., Eisenberg E.J., Cundy K.C., Sweet C., Jakeman K.J., Merson J., Lew W., Williams M., Zhang L., Kim C.U., Bischofberger N., Chen M.S., and Mendel D.B. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents Chemother. 42 (1998) 647-653
128. Doucette K.E., and Aoki F.Y. Oseltamivir: A clinical and pharmacological perspective. Expert Opin. Pharmacother. 2 (2001) 1671-1683
129. McCullers J.A. Antiviral therapy of influenza. Expert Opin. Investig. Drugs 14 (2005) 305-312
130. Yeung Y.Y., Hong S., and Corey E.J. A short enantioselective pathway for the synthesis of the anti-influenza neuramidase inhibitor oseltamivir from 1,3-butadiene and acrylic acid. J. Am. Chem. Soc. 128 (2006) 6310-6311
131. Harrington P.J., Brown J.D., Foderaro T., and Hughes R.C. Research and development of a second-generation process for oseltamivir phosphate, prodrug for a neuraminidase inhibitor. Org. Process Res. Dev. 8 (2004) 86-91
132. Abrecht S., Harrington P., Iding H., Karpf M., Trussardi R., Wirz B., and Zutter U. The synthetic development of the anti-influenza neuraminidase inhibitor oseltamivir phosphate (Tamiflu): A challenge for synthesis & process research. Chimia 58 (2004) 621-929
133. Jeong J.W., Kim J.K., Woo B.W., Song B.J., Ha D.C., and Z N. A substrate mimetic approach for influenza neuraminidase inhibitors. Bull. Korean Chem. Soc. 25 (2004) 1575-1577
134. Yamamoto T., Kumazawa H., Inami K., Teshima T., and Shiba T. Syntheses of sialic acid isomers with inhibitory activity against neuraminidase. Tetrahedron Lett. 33 (1992) 5791-5794
135. Babu Y.S., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Elliott A.J., Parker C.D., Ananth S.L., Horn L.L., Laver G.W., and Montgomery J.A. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 43 (2000) 3482-3486
136. Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Babu Y.S., Bantia S., Elliott A.J., and Montgomery J.A. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J. Med. Chem. 44 (2001) 4379-4392
137. Sidwell R.W., and Smee D.F. Peramivir (BCX-1812, RWJ-270201): Potential new therapy for influenza. Expert Opin. Investig. Drugs 11 (2002) 859-869
138. Bantia S., Arnold C.S., Parker C.D., Upshaw R., and Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 69 (2006) 39-45
139. Bantia S., Parker C.D., Ananth S.L., Horn L.L., Andries K., Chand P., Kotian P.L., Dehghani A., El-Kattan Y., Lin T., Hutchison T.L., Montgomery J.A., Kellog D.L., and Babu Y.S. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45 (2001) 1162-1167
140. Sidwell R.W., Smee D.F., Huffman J.H., Barnard D.L., Bailey K.W., Morrey J.D., and Babu Y.S. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob. Agents Chemother. 45 (2001) 749-757
141. Smee D.F., Huffman J.H., Morrison A.C., Barnard D.L., and Sidwell R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob. Agents Chemother. 45 (2001) 743-748
142. Chand P., Babu Y.S., Bantia S., Rowland S., Dehghani A., Kotian P.L., Hutchison T.L., Ali S., Brouillette W., El-Kattan Y., and Lin T.H. Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives. J. Med. Chem. 47 (2004) 1919-1929
143. Kati W.M., Montgomery D., Carrick R., Gubareva L., Maring C., McDaniel K., Steffy K., Molla A., Hayden F., Kempf D., and Kohlbrenner W. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46 (2002) 1014-1021
144. Wang G.T., Chen Y., Wang S., Gentles R., Sowin T., Kati W., Muchmore S., Giranda V., Stewart K., Sham H., Kempf D., and Laver W.G. Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J. Med. Chem. 44 (2001) 1192-1201
145. Kati W.M., Montgomery D., Maring C., Stoll V.S., Giranda V., Chen X., Laver W.G., Kohlbrenner W., and Norbeck D.W. Novel α- and β-amino acid inhibitors of influenza virus neuraminidase. Antimicrob. Agents Chemother. 45 (2001) 2563-2570
146. Wang G.T. Recent advances in the discovery and development of anti-influenza drugs. Expert Opin. Ther. Patents 12 (2002) 845-861
147. Wang G.T., Wang S., Gentles R., Sowin T., Maring C.J., Kempf D.J., Kati W.M., Stoll V., Stewart K.D., and Laver G. Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core. Bioorg. Med. Chem. Lett. 15 (2005) 125-128
148. Maring C.J., Stoll V.S., Zhao C., Sun M., Krueger A.C., Stewart K.D., Madigan D.L., Kati W.M., Xu Y., Carrick R.J., Montgomery D.A., Kempf-Grote A., Marsh K.C., Molla A., Steffy K.R., Sham H.L., Laver W.G., Gu Y.G., Kempf D.J., and Kohlbrenner W.E. Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors. J. Med. Chem. 48 (2005) 3980-3990
149. DeGoey D.A., Chen H.J., Flosi W.J., Grampovnik D.J., Yeung C.M., Klein L.L., and Kempf D.J. Enantioselective synthesis of antiinfluenza compound A-315675. J. Org. Chem. 67 (2002) 5445-5453
150. Hanessian S., Bayrakdarian M., and Luo X. Total synthesis of A-315675: A potent inhibitor of influenza neuraminidase. J. Am. Chem. Soc. 124 (2002) 4716-4721
151. Russell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 (2006) 45-49